Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
Type:
Grant
Filed:
April 6, 2021
Date of Patent:
March 21, 2023
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Birgit Wilding, Dietrich Boese, Harald Engelhardt, Julian Fuchs, Ralph Neumueller, Mark Petronczki, Dirk Scharn, Matthias Treu
Abstract: Methods of protein production in continuous perfusion mammalian cell culture bioreactors are provided. Methods for continuous perfusion culture by allowing cells to self-regulate the rate of addition of perfusion medium to the bioreactor via a pH change are presented. Compositions comprising the perfusion medium as well as the process advantages of using hi-end pH control of perfusion or HIPCOP are also presented.
Type:
Grant
Filed:
May 27, 2016
Date of Patent:
March 7, 2023
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Gregory Walter Hiller, Matthew Paul Gagnon, Ana Maria Ovalle
Abstract: The present invention relates to pesticidal and parasiticidal isoxazoline of formula (I) and salts thereof: wherein variables R1, P, Y and Q are described herein are as defined in the description. The invention also relates to parasiticidal and pesticidal compositions comprising the isoxazoline compounds of formula (I), processes for their preparation and their uses to prevent or treat parasitic infections or infestations in animals and as pesticides.
Type:
Grant
Filed:
August 14, 2018
Date of Patent:
February 28, 2023
Assignee:
BOEHRINGER INGELHEIM ANIMAL
HEALTH USA INC.
Abstract: This invention relates to compositions for combating ectoparasites and endoparasites in animals, comprising eprinomectin and praziquantel in combination with a pharmaceutically acceptable carrier, and optionally an antioxidant. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.
Type:
Grant
Filed:
February 7, 2019
Date of Patent:
February 21, 2023
Assignee:
BOEHRINGER INGELHEIM ANIMAL
HEALTH USA INC.
Abstract: The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
Type:
Grant
Filed:
January 28, 2019
Date of Patent:
February 21, 2023
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Thomas Trieselmann, Cedrickx Godbout, Christoph Hoenke, Viktor Vintonyak
Abstract: The invention describes anti-cancer therapies comprising using an LRP5 antagonist in combination with an anti-PD1 antibody, each as described herein.
Type:
Grant
Filed:
March 26, 2020
Date of Patent:
February 14, 2023
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Vittoria Zinzalla, Markus Johann Bauer, Barbara Drobits-Handl
Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
Type:
Grant
Filed:
September 1, 2021
Date of Patent:
February 14, 2023
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Martin Thomas Fleck, Florian Paul Christian Binder, Georg Dahmann, Joerg P. Hehn, Annekatrin Charlotte Heimann, Uta Friederike Lessel, Jens Willwacher
Abstract: The present invention relates to anti-SIRP? (Signal regulatory protein alpha) antibodies and antigen-binding fragments thereof for therapeutic and diagnostic methods and compositions using them.
Type:
Grant
Filed:
June 2, 2022
Date of Patent:
February 7, 2023
Assignees:
Boehringer Ingelheim International GmbH, OSE Immmnotherapeatics SA
Abstract: It is disclosed an improved multi-step process for the preparation of a highly concentrated liquid formulation containing biomolecules comprising the steps of (a) a first ultrafiltration UF1; (b) a first diafiltration DF1; (c) a second diafiltration DF2; and (d) a second ultrafiltration UF2; wherein an aqueous solution of one or more salts, as liquid medium B, is used for step (b) and water or an aqueous solution of one or more salts, as liquid medium C, is used for step (c), wherein the one or more salts used for step (b) are the same or different from the one or more salts used for step (c) and wherein the liquid medium B has an ionic strength which is higher than the ionic strength of the liquid medium C. The process according to the present invention allows the preparation of well-defined highly concentrated formulations containing biomolecules, particularly proteins, intended for pharmaceutical or non-pharmaceutical use.
Type:
Grant
Filed:
August 11, 2017
Date of Patent:
February 7, 2023
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Patrick Garidel, Sven Bahrenburg, Torsten Schultz-Fademrecht, Andrea Eiperle
Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.
Type:
Grant
Filed:
December 16, 2020
Date of Patent:
January 31, 2023
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Masanori Ito, Kenji Egusa, Roman Messerschmid, Peter Schneider
Abstract: The present invention relates to the identification of a genomic integration site for heterologous polynucleotides in Chinese Hamster Ovary (CHO) cells resulting in high RNA and/or protein production. More specifically it relates to CHO cells comprising at least one heterologous polynucleotide stably integrated into the S100A gene cluster of the CHO genome and to methods for the production of said CHO cells. Further, the invention relates to a method for the production of a protein of interest using said CHO cell and to the use of said CHO cell for producing a protein of interest at high yield. Integration within these specific target regions leads to reliable, stable and high yielding production of an RNA and/or protein of interest, encoded by the heterologous polynucleotide.
Type:
Grant
Filed:
August 10, 2018
Date of Patent:
January 24, 2023
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Markus Mueller, Jochen Schaub, Christian Bernloehr, Jennifer Koenitzer
Abstract: A system and method are disclosed for tracking animals, which may include production animals as well as pets. The system and method may comprise a tag system that is attached to an animal that generally has at least a near-field-communication (NFC) tag. The tag system comprises at least an NFC tag and a radio-frequency identification (RFID) tag. For NFC tags, such tags may be read with a portable computing device, such as a mobile telephone running NFC reader application software. The phone may communicate with a communications network and ultimately a computer server in order to relay information received from a respective electronic tag. The electronic tags may be fastened, embedded, or ingested by an animal. The electronic tags may be part of a mechanical coupling. Each mechanical coupling may comprise a different structure depending on the whether the tags are fastened to, embedded in, or ingested by the animal.
Abstract: The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.
Type:
Grant
Filed:
June 15, 2017
Date of Patent:
January 17, 2023
Assignees:
Sanofi Pasteur SA, Boehringer Ingelheim Animal Health USA Inc.
Inventors:
Guillaume Rigaut, Alexis Guy André Lucien Parisot, Karelle De Luca, Christine Michele Pierrette Andreoni, Lydie Remolue, Marie Garinot, Jean-François Cotte, Patricia Probeck-Quellec, Jean Haensler, Véronique Chambon, Philippe Talaga
Abstract: The invention relates to the field of cell culture technology. It concerns the knockdown, using RNA interference, or gene knockout, of activating transcription factor 6 beta (ATF6B), or the combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1D20) proteins, which play central roles in the cellular secretion pathway. This downregulation leads to improved secretion of biopharmaceutically relevant products produced in mammalian cells. The invention specifically relates to mammalian cells having enhanced secretion of a recombinant therapeutic protein compared to a control cell, a method of producing said mammalian cell, a method for the production of a recombinant secreted therapeutic protein and the use of said mammalian cell for increasing the yield of a recombinant secreted therapeutic protein.
Type:
Grant
Filed:
November 2, 2020
Date of Patent:
January 10, 2023
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Monilola Olayioye, Angelika Hausser, Lisa Pieper, Michaela Strotbek, Till Wenger
Abstract: The present invention provides an effective vaccine for Marek's disease, which may be prepared using a recombinant Marek's Disease Virus (MDV), strain CVI988, having been transformed with a foreign DNA construct that includes a long terminal repeat sequence of a reticuloendotheliosis virus. This safe viral agent elicits a highly protective immune response in a chicken against virulent MDV challenge without causing a significant degree of pathogenicity. Suitable formulations of the vaccine for use in chickens include an effective immunization dosage of this novel viral agent, along with a pharmaceutically acceptable carrier or diluent.
Type:
Grant
Filed:
January 30, 2019
Date of Patent:
November 29, 2022
Assignee:
Boehringer Ingelheim Animal Health
USA Inc.
Inventors:
Joyce Pritchard, Teshome Mebatsion, Michel Bublot
Abstract: The present invention provides a basal cell culture medium and a feed medium with novel amino acid ratios and/or iron choline citrate as iron carrier that result in improved performance of mammalian cell culture processes, such as CHO cultivation and protein production processes, in particular in increased product titer (e.g. of monoclonal antibodies). Also provided are methods for culturing mammalian cells and producing a protein of interest using said basal cell culture medium and optionally feed medium. The invention also provides for a medium platform that comprises (i) the basal cell culture medium and (ii) the feed medium.
Type:
Grant
Filed:
March 31, 2016
Date of Patent:
November 22, 2022
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Christoph Clemens, Jochen Schaub, Marie Link, Peter Schorn, Torsten Schulz
Abstract: This invention relates to long-acting injectable compositions for combating parasites in animals, comprising at least one isoxazoline active agent, a liquid PEG and/or a neutral oil, optionally a co-solvent, and optionally a pharmaceutically acceptable additive or excipient. This invention also provides new isoxazoline active agents with long-lasting efficacy against ectoparasites. The invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the novel isoxazoline compounds and long-acting injectable compositions of the invention to the animal in need thereof.
Type:
Grant
Filed:
August 7, 2019
Date of Patent:
November 15, 2022
Assignee:
BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Inventors:
Loic Patrick Le Hir de Fallois, Charles Q. Meng, Susan Mancini Cady, Peter Cheifetz, Izabela Galeska
Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
Type:
Grant
Filed:
October 14, 2020
Date of Patent:
March 7, 2023
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Cédrickx Godbout, Thomas Trieselmann, Viktor Vintonyak